Scientists have created a new type of drug, called KTX207, that works by specifically instructing cells to destroy certain proteins, rather than just blocking them. This new drug targets a group of proteins called PDE4 shortforms. By getting rid of these proteins, KTX207 is much better at increasing a vital molecule in cells called cAMP. This leads to significantly stronger anti-inflammatory effects and better control over the growth of cancer cells, even when used for a short time. This new way of treating diseases by eliminating specific proteins could lead to safer and more effective medicines in the future.
Funding
–
Original Paper
Title of original paper: Targeted protein degradation of PDE4 shortforms by a novel proteolysis targeting chimera
Journal: FEBS Journal (FEBS J)
DOI: 10.1111/febs.17359
Correspondence
Yuan Yan Sin, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow G12 8QQ, UK
E-mail: [email protected]